[Pharmacokinetic and clinical studies on meropenem].
Pharmacokinetic and clinical studies on meropenem (MEPM, SM-7338), a new developed carbapenem, were performed and the following results were obtained. 1. Absorption/excretion: Pharmacokinetics of MEPM was studied in 9 children using doses of 10 mg/kg and 20 mg/kg by a 30 minute-drip infusion. Peak plasma levels and plasma half-lives of the 2 doses were 28.4 and 43.0 micrograms/ml, and 0.70 and 0.80 hours, respectively. Their urinary recovery rates were 42.5 to 67.6% and 29.9 to 62.6%, respectively. Cerebrospinal fluid levels and penetration rates of MEPM in a patient with purulent meningitis were 0.66 to 4.01 micrograms/ml and 1.6 to 12.2%, respectively. 2. Clinical study: Forty-nine patients were treated with MEPM at doses exceeding 100 mg/kg/day with purulent meningitis and 30 to 60 mg/kg/day with other infections. MEPM gave "excellent" or "good" responses in 48 cases, an efficacy rate of 98.0%. Only one patient with subdural abscess showed fair response. Diarrhea and rash were observed in 1 case each. Abnormal laboratory test results were noted in 5 patients including elevation of GOT, GPT and eosinophils. In no cases the treatment had to be discontinued.
Toyonaga
Y
Y
Department of Pediatrics, Yamanashi Red Cross Hospital.
Yamori
K
K
Hatakeyama
K
K
Ishihara
T
T
Kawamura
K
K
Seo
K
K
Nakamura
H
H
Okabe
N
N
Toyoda
S
S
Katayama
A
A
D000042:Absorption; D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D008099:Liver / Q000187:drug effects; D008297:Male; D016920:Meningitis, Bacterial / Q000134:cerebrospinal fluid / Q000188:drug therapy; D000077731:Meropenem; D013845:Thienamycins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D013845:Thienamycins; D000077731:Meropenem